Fulcrum Total Liab vs Non Current Assets Total Analysis

FULC Stock

USD 3.44 0.19 5.85%

Fulcrum Therapeutics financial indicator trend analysis is much more than just examining Fulcrum Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulcrum Therapeutics is a good investment. Please check the relationship between Fulcrum Therapeutics Total Liab and its Non Current Assets Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

Total Liab vs Non Current Assets Total

Total Liab vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulcrum Therapeutics Total Liab account and Non Current Assets Total. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Fulcrum Therapeutics' Total Liab and Non Current Assets Total is 0.92. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Fulcrum Therapeutics, assuming nothing else is changed. The correlation between historical values of Fulcrum Therapeutics' Total Liab and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Fulcrum Therapeutics are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Total Liab i.e., Fulcrum Therapeutics' Total Liab and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

0.92

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Most indicators from Fulcrum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 15.60, whereas Selling General Administrative is forecasted to decline to about 25.3 M.

	2018	2019	2023	2024 (projected)
Interest Income	518K	1.5M	1.7M	1.8M
Net Interest Income	518K	1.5M	1.7M	1.8M

Interest Income Net Interest Income

Fulcrum Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.62	0.81	1.0	0.26	0.93	0.27	-0.42	-0.93	0.81	0.54	0.87	-0.02	0.9	1.0	0.81	0.95	0.92	0.83	0.93	-0.52	0.9	0.99	0.87	1.0	0.7
Other Current Liab	0.62		0.74	0.59	0.36	0.66	0.46	-0.41	-0.69	0.52	0.52	0.82	-0.24	0.71	0.61	0.36	0.67	0.61	0.83	0.68	-0.45	0.34	0.68	0.82	0.61	0.53
Total Current Liabilities	0.81	0.74		0.78	0.5	0.81	0.27	-0.51	-0.74	0.93	0.59	0.84	-0.04	0.72	0.81	0.85	0.77	0.66	0.76	0.78	-0.7	0.58	0.78	0.97	0.8	0.49
Total Stockholder Equity	1.0	0.59	0.78		0.22	0.93	0.24	-0.38	-0.92	0.79	0.51	0.85	0.0	0.9	1.0	0.81	0.94	0.93	0.8	0.93	-0.5	0.92	0.99	0.83	1.0	0.71
Other Liab	0.26	0.36	0.5	0.22		0.14	0.74	-0.95	-0.04	0.28	0.88	0.39	-0.68	0.09	0.26	0.27	0.15	-0.06	0.56	0.08	0.1	-0.09	0.18	0.55	0.29	0.08
Net Tangible Assets	0.93	0.66	0.81	0.93	0.14		0.28	-0.25	-0.97	0.84	0.41	0.78	-0.04	0.92	0.94	0.78	0.96	0.87	0.76	0.99	-0.51	0.86	0.94	0.84	0.92	0.75
Property Plant And Equipment Net	0.27	0.46	0.27	0.24	0.74	0.28		-0.74	-0.19	0.09	0.75	0.32	-0.96	0.23	0.26	-0.03	0.26	0.01	0.64	0.23	0.46	0.03	0.23	0.43	0.29	0.23
Net Debt	-0.42	-0.41	-0.51	-0.38	-0.95	-0.25	-0.74		0.2	-0.29	-0.98	-0.56	0.63	-0.29	-0.41	-0.29	-0.32	-0.11	-0.71	-0.22	-0.06	-0.06	-0.33	-0.61	-0.45	-0.25
Retained Earnings	-0.93	-0.69	-0.74	-0.92	-0.04	-0.97	-0.19	0.2		-0.73	-0.38	-0.83	-0.07	-0.98	-0.92	-0.7	-0.99	-0.93	-0.77	-0.99	0.56	-0.84	-0.95	-0.8	-0.91	-0.84
Accounts Payable	0.81	0.52	0.93	0.79	0.28	0.84	0.09	-0.29	-0.73		0.37	0.68	0.1	0.65	0.81	0.91	0.74	0.67	0.59	0.78	-0.68	0.73	0.77	0.85	0.79	0.38
Cash	0.54	0.52	0.59	0.51	0.88	0.41	0.75	-0.98	-0.38	0.37		0.68	-0.59	0.47	0.53	0.35	0.49	0.26	0.82	0.4	-0.02	0.18	0.47	0.71	0.58	0.42
Non Current Assets Total	0.87	0.82	0.84	0.85	0.39	0.78	0.32	-0.56	-0.83	0.68	0.68		-0.03	0.88	0.86	0.62	0.87	0.79	0.93	0.82	-0.6	0.61	0.87	0.92	0.87	0.66
Non Currrent Assets Other	-0.02	-0.24	-0.04	0.0	-0.68	-0.04	-0.96	0.63	-0.07	0.1	-0.59	-0.03		0.05	-0.02	0.22	0.02	0.22	-0.4	0.03	-0.67	0.15	0.01	-0.18	-0.04	0.0
Other Assets	0.9	0.71	0.72	0.9	0.09	0.92	0.23	-0.29	-0.98	0.65	0.47	0.88	0.05		0.9	0.63	0.99	0.89	0.83	0.96	-0.55	0.76	0.92	0.8	0.9	0.88
Cash And Short Term Investments	1.0	0.61	0.81	1.0	0.26	0.94	0.26	-0.41	-0.92	0.81	0.53	0.86	-0.02	0.9		0.82	0.94	0.92	0.82	0.93	-0.52	0.9	0.99	0.86	1.0	0.7
Net Receivables	0.81	0.36	0.85	0.81	0.27	0.78	-0.03	-0.29	-0.7	0.91	0.35	0.62	0.22	0.63	0.82		0.72	0.71	0.49	0.74	-0.7	0.74	0.77	0.76	0.8	0.5
Common Stock Total Equity	0.95	0.67	0.77	0.94	0.15	0.96	0.26	-0.32	-0.99	0.74	0.49	0.87	0.02	0.99	0.94	0.72		0.9	0.83	0.99	-0.53	0.83	0.95	0.84	0.94	0.85
Common Stock Shares Outstanding	0.92	0.61	0.66	0.93	-0.06	0.87	0.01	-0.11	-0.93	0.67	0.26	0.79	0.22	0.89	0.92	0.71	0.9		0.68	0.9	-0.61	0.89	0.96	0.71	0.91	0.73
Non Current Liabilities Total	0.83	0.83	0.76	0.8	0.56	0.76	0.64	-0.71	-0.77	0.59	0.82	0.93	-0.4	0.83	0.82	0.49	0.83	0.68		0.78	-0.29	0.55	0.82	0.9	0.84	0.65
Capital Surpluse	0.93	0.68	0.78	0.93	0.08	0.99	0.23	-0.22	-0.99	0.78	0.4	0.82	0.03	0.96	0.93	0.74	0.99	0.9	0.78		-0.55	0.85	0.94	0.82	0.92	0.81
Inventory	-0.52	-0.45	-0.7	-0.5	0.1	-0.51	0.46	-0.06	0.56	-0.68	-0.02	-0.6	-0.67	-0.55	-0.52	-0.7	-0.53	-0.61	-0.29	-0.55		-0.42	-0.54	-0.58	-0.49	-0.37
Other Current Assets	0.9	0.34	0.58	0.92	-0.09	0.86	0.03	-0.06	-0.84	0.73	0.18	0.61	0.15	0.76	0.9	0.74	0.83	0.89	0.55	0.85	-0.42		0.9	0.6	0.88	0.54
Other Stockholder Equity	0.99	0.68	0.78	0.99	0.18	0.94	0.23	-0.33	-0.95	0.77	0.47	0.87	0.01	0.92	0.99	0.77	0.95	0.96	0.82	0.94	-0.54	0.9		0.84	0.98	0.72
Total Liab	0.87	0.82	0.97	0.83	0.55	0.84	0.43	-0.61	-0.8	0.85	0.71	0.92	-0.18	0.8	0.86	0.76	0.84	0.71	0.9	0.82	-0.58	0.6	0.84		0.86	0.58
Net Invested Capital	1.0	0.61	0.8	1.0	0.29	0.92	0.29	-0.45	-0.91	0.79	0.58	0.87	-0.04	0.9	1.0	0.8	0.94	0.91	0.84	0.92	-0.49	0.88	0.98	0.86		0.71
Property Plant And Equipment Gross	0.7	0.53	0.49	0.71	0.08	0.75	0.23	-0.25	-0.84	0.38	0.42	0.66	0.0	0.88	0.7	0.5	0.85	0.73	0.65	0.81	-0.37	0.54	0.72	0.58	0.71

Click cells to compare fundamentals

Fulcrum Therapeutics Account Relationship Matchups

Fulcrum Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	110.4M	129.6M	235M	226.7M	257.7M	164.9M
Other Current Liab	5.9M	7.7M	74K	6.9M	6.5M	4.5M
Total Current Liabilities	12.1M	26.7M	19.2M	16.7M	13.7M	15.0M
Total Stockholder Equity	87.2M	95.2M	211.5M	198.9M	235.2M	142.3M
Other Liab	11.1M	7.7M	4.3M	197K	177.3K	168.4K
Net Tangible Assets	87.2M	95.2M	211.5M	198.9M	228.8M	240.2M
Property Plant And Equipment Net	87.9M	8.4M	7.4M	16.0M	12.4M	16.6M
Net Debt	(96.7M)	(57.0M)	(35.4M)	(21.7M)	(14.7M)	(15.5M)
Retained Earnings	(150.8M)	(221.6M)	(302.5M)	(412.3M)	(509.7M)	(484.2M)
Accounts Payable	2.2M	4.1M	4.8M	3.6M	2.8M	3.2M
Cash	96.7M	57.1M	35.4M	35.1M	25.6M	36.9M
Non Current Assets Total	10.4M	16.7M	9.0M	19.2M	15.5M	13.4M
Non Currrent Assets Other	(78.7M)	7.2M	542K	2.1M	3.1M	3.3M
Other Assets	1.2M	1.7M	1.6M	3.2M	3.7M	3.9M
Cash And Short Term Investments	96.7M	112.9M	218.2M	202.9M	236.2M	147.7M
Net Receivables	111K	2.7M	4.1M	1.1M	2.2M	1.7M
Common Stock Total Equity	23K	28K	41K	52K	59.8K	62.8K
Common Stock Shares Outstanding	11.0M	25.4M	35.4M	45.0M	61.3M	32.4M
Liabilities And Stockholders Equity	110.4M	129.6M	235M	226.7M	257.7M	164.9M
Non Current Liabilities Total	11.1M	7.7M	4.3M	11.0M	8.8M	7.7M
Capital Surpluse	237.9M	316.8M	514.4M	612.0M	703.8M	739.0M
Capital Lease Obligations	46K	50K	17K	13.4M	10.8M	11.4M
Inventory	3.0M	(2.8M)	(473K)	(852K)	(766.8K)	(728.5K)
Other Current Assets	284K	74K	4.2M	3.5M	3.7M	1.9M
Other Stockholder Equity	237.9M	316.8M	514.4M	612.0M	744.9M	404.7M
Total Liab	23.3M	34.4M	23.5M	27.7M	22.5M	22.7M
Net Invested Capital	87.2M	95.2M	211.5M	198.9M	235.2M	136.8M
Property Plant And Equipment Gross	9.2M	8.4M	7.4M	6.9M	25.2M	26.4M
Total Current Assets	100.1M	112.9M	226.0M	207.5M	242.2M	151.5M
Accumulated Other Comprehensive Income	(110.4M)	(2K)	(397K)	(797K)	(136K)	(142.8K)
Non Current Liabilities Other	150K	55K	3.1M	197K	226.6K	215.2K
Net Working Capital	87.9M	92.8M	206.8M	190.8M	228.5M	137.5M
Short Term Debt	50K	17K	9.6M	5.2M	4.4M	3.0M
Common Stock	23K	28K	41K	52K	62K	35.0K
Property Plant Equipment	9.2M	8.4M	7.4M	6.9M	7.9M	8.3M
Short Long Term Debt Total	50K	17K	469K	13.4M	10.8M	11.4M
Current Deferred Revenue	4.0M	14.9M	4.7M	934K	840.6K	798.6K
Capital Stock	23K	28K	41K	52K	62K	40.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:

How To Invest In Fulcrum

Details

Is Fulcrum Stock a good investment?

Details

What is Fulcrum Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.29)

Revenue Per Share

1.317

Quarterly Revenue Growth

89.909

Return On Assets

(0.07)

Return On Equity

(0.07)

The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fulcrum Total Liab vs Non Current Assets Total Analysis

Total Liab vs Non Current Assets Total

Total Liab vs Non Current Assets Total Correlation Analysis

Correlation Coefficient

Total Liab

Non Current Assets Total

Fulcrum Therapeutics fundamental ratios Correlations

Fulcrum Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fulcrum Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Cash And Short Term Investments

Capital Surpluse	- 0.99	Retained Earnings
Common Stock Total Equity	- 0.99	Retained Earnings
Other Assets	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Net Tangible Assets
Non Currrent Assets Other	- 0.96	Property Plant And Equipment Net